INVION PRESENTS DATA TO US MARKET

INVION PRESENTS DATA TO US MARKET

RESPIRATORY technology company Invion Limited (ASX:IVX) has delivered findings from its trial of oral nadolol to international medical experts at a conference in the US.

The Brisbane-based company attended the American Thoracic Society (ATS) meeting to present data from its ongoing study of INV102.

The trial uses the lead compound to assist patients experiencing chronic cough while attempting to give up cigarettes.

Early results show that key signs of respiratory inflammation could be reduced in four weeks of treatment, as opposed to the placebo.

Lead study investigators Dr Mario Castro and Geneline Sajol from Washington University say they decided to open the trial to patients without chronic obstructive pulmonary disorder (COPD).

Oral nadolol could be safely administered to patients with "smokers cough" as well as cases of COPD.

"On examining baseline biomarkers, we found no difference in COPD versus non-COPD subjects," Castro says.

"What this essentially means is that we now believe we can safely target the smoking population with or without diagnosed COPD, because of the similarities in airway inflammation."

Nadolol is currently used to treat high blood pressure and migraine. Invion is repurposing the drug to treat asthma and COPD.

The global market opportunity for inflammatory airway disease treatment is estimated to be worth $34 billion.

Get our daily business news

Sign up to our free email news updates.

 
Whitefox Recruitment founder Luke Hemmings making strides as a careers leader
Partner Content
After relocating his Canberra-founded company Whitefox Recruitment to the Gold Coast la...
Whitefox Recruitment
Advertisement

Related Stories

ASIC secures its first court win for greenwashing against US giant Vanguard

ASIC secures its first court win for greenwashing against US giant Vanguard

The Australian corporate watchdog has caught out one of the world&r...

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Australian-founded medicinal cannabis company Althea Group (ASX: AG...

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Listed funds manager 360 Capital Group (ASX: TGP) has offloaded its...

The party’s over: Splendour in the Grass festival cancelled for 2024

The party’s over: Splendour in the Grass festival cancelled for 2024

Splendour in the Grass, Australia’s largest winter music fest...